CVRx Q1 revenue $10.8M (+35% YoY); net loss $22.2M; FY guidance $50-53M

CVRx, Inc.

2024-Q1 EPS reported -$1.04 revenue$10,770,000

Q1 revenue $10.8M (+35% YoY); US HF revenue $9.7M (+43%); active implanting centers 190 (+56% YoY).
Net loss $22.2M ($1.04/shr) vs $11.4M ($0.55) prior year; SG&A $28.3M (+84%) from stock-based comp modification for former CEO.
Full-year 2024 revenue guidance $50-53M; Q2 2024 revenue expected $11.3-12.3M.
Kevin Hykes appointed CEO Feb 12; BeAT-HF data published in European Journal of Heart Failure.
Compensation Committee approved $50k bonus to Paul Verrastro for management transition support.

item 2.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CVRx, Inc. reported the first quarter of 2024 results: revenue $10.8 million, net income $22.2 million, or $1.04 per share, EPS $1.04 per share. Guidance reaffirmed.

Period: the first quarter of 2024
Revenue: $10.8 million
Net income: $22.2 million, or $1.04 per share
EPS: $1.04 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights · Total revenue for the first quarter 2024 was $ 10.8 million, an increase of 35 % over the prior year quarter · U.S. Heart Failure (HF) revenue for the first quarter of 2024 was $ 9.7 million, an increase of 43 % over the prior year

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

CVRx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-054933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.